SARS coronavirus 2 (SARS-CoV-2), more commonly known as coronavirus disease (COVID-19), has impacted the people of Oregon with over 36,000 total cases and over 600 deaths reported as of October 2020. Testing for this virus is critical for case identification to slow the disease spread and ensure infected persons are triaged to receive appropriate patient care. Fortunately, testing for COVID-19 has become more accessible for individuals as the COVID-19 pandemic has persisted. However, confusion still exists for many patients and practitioners regarding COVID-19 testing recommendations. The focus of this newsletter is to clarify who should be tested, timing of tests and where to receive the COVID-19 test in Oregon.

COVID-19 Testing Approval
The Oregon Health Authority (OHA) recommends using only tests that have emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA). On February 4th, 2020 the Department of Health and Human Services issued an EUA under the Public Readiness and Emergency Preparedness Act (PREP). This EUA allows for unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious disease, in this case COVID-19. Technologies and therapies under EUA have not undergone full FDA scrutiny and these authorizations are not FDA-approvals. Likely, once the COVID-19 pandemic is declared over, the EUA will expire as seen in the EUA expiration of peramivir in 2010 after the 2009 H1N1 influenza pandemic. Additionally, the EUA could be revoked if deemed appropriate by the FDA.

Types of COVID-19 Tests
Three types of tests are available for COVID-19: viral tests (e.g., molecular based and antigen tests) and serologic (antibody) tests. A viral test tells individuals if they have a current infection with COVID-19, while an antibody test might tell individuals if they have had a past infection. Antibody testing is occurring at certain locations around Oregon, however, the OHA states there is insufficient evidence to suggest that antibody tests are a reliable indicator that an individual has or had COVID-19 or that they have immunity. Therefore, COVID-19 testing referenced in the remainder of this article will refer to viral testing, as there is uncertainty with antibody testing.

Viral tests can be conducted via one of two technologies: a molecular test or an antigen test. Molecular tests detect viral ribonucleic acid (RNA) via reverse transcription polymerase chain reaction (RT-PCR) process and is considered the gold standard. The second method is rapid antigen testing which detects the presence of the nucleocapsid protein antigen. Both test detect active viral COVID-19 infection. Viral testing using RT-PCR provides results in less than an hour to more than 2 days. Rapid antigen tests take approximately 15 minutes but are less sensitive than molecular assays. Rapid antigen testing is most accurate in the early stages of infection, when there is higher viral loads. Rapid antigen testing may require confirmation with RT-PCR within 2 days as a confirmatory test. Both of these tests, antigen and molecular, can be conducted as either a point-of-care (POC) test or lab processed test.

Accuracy of the testing methods is determined by sensitivity and specificity. The sensitivity of a test refers to the ability of the test to correctly identify those with a disease compared with specificity, which allows a test to identify those patients without disease. A recent Cochrane review found the average sensitivity of the antigen tests to be 56.2% (95% confidence interval [CI], 29.5% to 79.8%) with an average specificity of 99.5% (95% CI, 98.1% to 99.9%). Sensitivity for the molecular assay test was higher with an average sensitivity of 95.2% (95% CI, 86.7% to 98.3%) and specificity of 98.9% (95% CI, 97.3% to 99.5%). The evidence was found to be at high risk of bias with an emphasis on the need for additional trials.

Testing Collection Methods
It is recommended that nasopharyngeal, mid-turbinate (MT) or nasal swabs be utilized for testing versus other testing collection methods. Accuracy of recommended collection sites range from 75% to 95% and are displayed in Table 1. Oral tests were 56% sensitive and saliva tests were 85% sensitive (and inconsistent); therefore, these testing sites are currently not preferred. Collection by the patient or healthcare worker was deemed appropriate for nasal and MT testing. Due to the quality of studies available, the certainty of the evidence is very low.

| Table 1. Accuracy of COVID-19 Results based on Collection Site% |
|------------------|------------------|------------------|
|                   | Nasal            | Nasopharyngeal   | Mid-turbinate   |
| Sensitivity (95% CI) | 76% (59% to 94%) | 97% (92% to 100%) | 100% (93% to 100%) |
| Specificity (95% CI) | 100% (99% to 100%) | 100% (99% to 100%) | 100% (99% to 100%) |

Key: * Bases on estimates of positive and negative test results in a hypothetical population of 1000 individuals.
Timing of Testing
Close contacts of confirmed or presumptive COVID-19 cases are recommended to be tested 3-14 days after exposure, although the optimal time for testing remains unknown. Recommendations for the timing of testing for other populations are as follows:
- Symptomatic individuals: tested as soon as possible.
- Patients undergoing surgery: ideally 48-72 hours before surgery.
- Patients undergoing immunosuppressive procedures: ideally 48-72 hours before procedure.

If suspicion is low for COVID-19 the Infectious Diseases Society of America (IDSA) recommends not repeating the test if results are negative; however, the test should be repeated in light of a negative test result if the patient is hospitalized or at high suspicion of having COVID-19. Repeat testing should take place within 24-48 hours of a negative test result if an individual is an appropriate candidate for repeat testing. If a patient tests positive, there is no need to retest for at least 3 months.

Recommendations for Who Should be Tested
OHA published updates in November 2021 for COVID-19 recommendations relating to viral testing for individuals with symptoms (Table 2) and without symptoms (Table 3). Additional guidance on who should receive testing if resources are limited is available on the OHA website. Per the Centers for Disease Control and Prevention (CDC), COVID-19 symptoms may appear 2-14 days after exposure to the virus.

Additionally, OHA recently recommends that close contacts of confirmed or presumptive COVID-19 cases, people exposed to COVID-19 in a congregate setting, and migrant/seasonal agricultural workers upon arrival in Oregon be tested for COVID-19 regardless of whether they have symptoms or not. Clinicians may order commercial tests based on their clinical judgement.

Interpreting COVID-19 Test Results to Patients
OHA has provided messaging for providers to utilize with patients regarding the accuracy of COVID-19 viral tests and antibody tests (Figure 1 and Figure 2). Patients should be considered non-contagious if it has been at least 10 days since symptom onset and fever free for at least 24 hours. If a patient has been in close contact with someone with COVID-19 and tests negative, they should still self-isolate for at least 14 days.

Where to Direct Individuals for Testing
OHA recommends individuals contact their primary healthcare provider or clinic if they believe they need testing. For individuals without a doctor, OHA has a phone number, 211.
that will provide individuals with help for finding nearby clinics that test for COVID-19. Additionally, the OHA website has a COVID-19 test site finder map that individuals can utilize by submitting their address, ZIP code, or city and a list of nearby COVID-19 testing sites will populate. Sites listed include clinics, urgent care sites, and pharmacies that test for COVID-19. Providers and other individuals can contribute to the map by submitting a new location that tests for COVID-19 on the interactive map. New locations are reviewed and the map is usually updated within 12 hours with the new location. Additionally, patients may be directed to their respective county website which lists COVID-19 testing sites in their region.

Oregon COVID-19 Testing Sites can be found at: https://govstatus.egov.com/or-oha-covid-19-testing

For testing sites in Oregon, the majority require appointments to be made ahead of time. This may prove to be difficult for patients who are not established with a primary care provider, do not have a phone, or do not have internet access to schedule an appointment. Two organizations that are currently accepting individuals for COVID-19 testing with no appointment required are: Oregon Health and Science University (OHSU): https://www.ohsu.edu/health/coronavirus-resources#section-1117926 Virginia Garcia Medical Center (select events): https://virginiagarcia.org/coronavirus/

Pharmacy Testing Sites
Some of the most convenient locations for patients to receive COVID-19 testing include pharmacies. Rite Aid and Walgreens have COVID-19 testing sites provided at no cost. Rite Aid currently has 17 locations and Walgreens has 2 locations performing COVID-19 tests in Oregon. Safeway and Albertsons are also offering testing at pharmacies but for an approximate cost of $140 each. Rite Aid: https://www.riteaid.com/pharmacy/services/covid-19-testing
Walgreens: https://www.walgreens.com/findcare/covid19/testing

Patients can access testing by completing a screening survey online to determine eligibility, receive an appointment for testing, have the test performed by the patient or pharmacist using a nasal swab, and have test results relayed back to the patient via email or phone call.

The Role of the Provider
Information regarding COVID-19 testing changes rapidly. In order to provide accurate information and minimize confusion, it is paramount that providers stay up to date on information regarding COVID-19 testing. Providers and patients can utilize reliable sources of information for COVID-19 testing, such as, the OHA and CDC. In this way, accurate and optimal patient care can be provided to the individuals of Oregon.

Additional information on Coronavirus Management can be found at https://pharmacy.oregonstate.edu/drug-policy/newsletters/coronavirus-management

Peer Reviewed By: James Lewis, Pharm.D., FIDSA, Clinical Supervisor for Infectious Disease, Oregon Health and Science University, Portland, Oregon

References: